A longitudinal program for biomarker development in Parkinson's disease: A feasibility study
Identifieur interne : 000B78 ( Main/Exploration ); précédent : 000B77; suivant : 000B79A longitudinal program for biomarker development in Parkinson's disease: A feasibility study
Auteurs : Bernard Ravina [États-Unis] ; Caroline Tanner [États-Unis] ; Diane Dieuliis [États-Unis] ; Shirley Eberly [États-Unis] ; Emily Flagg [États-Unis] ; Wendy R. Galpern [États-Unis] ; Stanley Fahn [États-Unis] ; Christopher G. Goetz [États-Unis] ; Stephen Grate [États-Unis] ; Roger Kurlan [États-Unis] ; Anthony E. Lang [Canada] ; Kenneth Marek [États-Unis] ; Karl Kieburtz [États-Unis] ; David Oakes [États-Unis] ; Robin Elliott [États-Unis] ; Ira Shoulson [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-10-30.
English descriptors
- KwdEn :
Abstract
Long‐term follow up is necessary to understand the natural history of treated Parkinson's disease (PD). The Longitudinal and Biomarker Study in PD (LABS‐PD) is an observational study designed to prospectively measure the evolution of motor and non‐motor features of PD and sample promising biomarkers from early to late stage illness. LABS‐PD is organized on the premise that cohorts from completed clinical trials can be re‐recruited for long‐term follow up. LABS‐PD will eventually contain multiple cohorts, but to test the feasibility of the strategy, we examined enrollment and biomarker sampling in the initial cohorts. The first PD cohort (PostCEPT) comes from the de novo clinical trial of a mixed lineage kinase inhibitor (PRECEPT). We assessed the recruitment from PRECEPT to PostCEPT, the ability to link data from the two studies, and sample collection for a variety of biomarkers. A total of 537 of 709 eligible PRECEPT subjects (76%) enrolled in PostCEPT; 509 (95%) had repeat dopamine transporter imaging. PRECEPT clinical and imaging data were successfully linked to PostCEPT, to provide 3 to 4 year follow‐up. A biomarker sub‐study enrolled over 100 PD cases from PostCEPT and 100 controls to measure olfaction and blood markers of gene expression, α‐synuclein, and proteomic profiles. We were also successful in linking clinical and biomarker data to DNA samples that have been collected in the publicly accessible Coriell repository. The PostCEPT cohort and associated studies strongly support the feasibility of the LABS‐PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22690
Affiliations:
- Canada, États-Unis
- Californie, Connecticut, Illinois, Maryland, État de New York
- New York
- Université Columbia
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A longitudinal program for biomarker development in Parkinson's disease: A feasibility study</title><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name></author><author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name></author><author><name sortKey="Dieuliis, Diane" sort="Dieuliis, Diane" uniqKey="Dieuliis D" first="Diane" last="Dieuliis">Diane Dieuliis</name></author><author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name></author><author><name sortKey="Flagg, Emily" sort="Flagg, Emily" uniqKey="Flagg E" first="Emily" last="Flagg">Emily Flagg</name></author><author><name sortKey="Galpern, Wendy R" sort="Galpern, Wendy R" uniqKey="Galpern W" first="Wendy R." last="Galpern">Wendy R. Galpern</name></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></author><author><name sortKey="Grate, Stephen" sort="Grate, Stephen" uniqKey="Grate S" first="Stephen" last="Grate">Stephen Grate</name></author><author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name></author><author><name sortKey="Elliott, Robin" sort="Elliott, Robin" uniqKey="Elliott R" first="Robin" last="Elliott">Robin Elliott</name></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C459F8C897606D94073150044749C8A83D0A7482</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22690</idno><idno type="url">https://api.istex.fr/document/C459F8C897606D94073150044749C8A83D0A7482/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000628</idno><idno type="wicri:Area/Main/Curation">000545</idno><idno type="wicri:Area/Main/Exploration">000B78</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A longitudinal program for biomarker development in Parkinson's disease: A feasibility study</title><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dieuliis, Diane" sort="Dieuliis, Diane" uniqKey="Dieuliis D" first="Diane" last="Dieuliis">Diane Dieuliis</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Flagg, Emily" sort="Flagg, Emily" uniqKey="Flagg E" first="Emily" last="Flagg">Emily Flagg</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Galpern, Wendy R" sort="Galpern, Wendy R" uniqKey="Galpern W" first="Wendy R." last="Galpern">Wendy R. Galpern</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region><settlement type="city">New York</settlement></placeName><orgName type="university">Université Columbia</orgName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurosciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Grate, Stephen" sort="Grate, Stephen" uniqKey="Grate S" first="Stephen" last="Grate">Stephen Grate</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Telemedicine and Advanced Technology Research Center, Fort Detrick, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Division of Neurology, Univerisity of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Neurodegenerative Disorders, New Haven, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Elliott, Robin" sort="Elliott, Robin" uniqKey="Elliott R" first="Robin" last="Elliott">Robin Elliott</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Disease Foundation, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-10-30">2009-10-30</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2081">2081</biblScope><biblScope unit="page" to="2090">2090</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C459F8C897606D94073150044749C8A83D0A7482</idno><idno type="DOI">10.1002/mds.22690</idno><idno type="ArticleID">MDS22690</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>biomarker</term><term>progression</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Long‐term follow up is necessary to understand the natural history of treated Parkinson's disease (PD). The Longitudinal and Biomarker Study in PD (LABS‐PD) is an observational study designed to prospectively measure the evolution of motor and non‐motor features of PD and sample promising biomarkers from early to late stage illness. LABS‐PD is organized on the premise that cohorts from completed clinical trials can be re‐recruited for long‐term follow up. LABS‐PD will eventually contain multiple cohorts, but to test the feasibility of the strategy, we examined enrollment and biomarker sampling in the initial cohorts. The first PD cohort (PostCEPT) comes from the de novo clinical trial of a mixed lineage kinase inhibitor (PRECEPT). We assessed the recruitment from PRECEPT to PostCEPT, the ability to link data from the two studies, and sample collection for a variety of biomarkers. A total of 537 of 709 eligible PRECEPT subjects (76%) enrolled in PostCEPT; 509 (95%) had repeat dopamine transporter imaging. PRECEPT clinical and imaging data were successfully linked to PostCEPT, to provide 3 to 4 year follow‐up. A biomarker sub‐study enrolled over 100 PD cases from PostCEPT and 100 controls to measure olfaction and blood markers of gene expression, α‐synuclein, and proteomic profiles. We were also successful in linking clinical and biomarker data to DNA samples that have been collected in the publicly accessible Coriell repository. The PostCEPT cohort and associated studies strongly support the feasibility of the LABS‐PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data. © 2009 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Californie</li><li>Connecticut</li><li>Illinois</li><li>Maryland</li><li>État de New York</li></region><settlement><li>New York</li></settlement><orgName><li>Université Columbia</li></orgName></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name></region><name sortKey="Dieuliis, Diane" sort="Dieuliis, Diane" uniqKey="Dieuliis D" first="Diane" last="Dieuliis">Diane Dieuliis</name><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name><name sortKey="Elliott, Robin" sort="Elliott, Robin" uniqKey="Elliott R" first="Robin" last="Elliott">Robin Elliott</name><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><name sortKey="Flagg, Emily" sort="Flagg, Emily" uniqKey="Flagg E" first="Emily" last="Flagg">Emily Flagg</name><name sortKey="Galpern, Wendy R" sort="Galpern, Wendy R" uniqKey="Galpern W" first="Wendy R." last="Galpern">Wendy R. Galpern</name><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><name sortKey="Grate, Stephen" sort="Grate, Stephen" uniqKey="Grate S" first="Stephen" last="Grate">Stephen Grate</name><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name></country><country name="Canada"><noRegion><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C459F8C897606D94073150044749C8A83D0A7482
|texte= A longitudinal program for biomarker development in Parkinson's disease: A feasibility study
}}
| This area was generated with Dilib version V0.6.23. |  |